Introduction {#Sec1}
============

Polycythemia vera (PV) is a myeloproliferative neoplasm (MPN) characterized by clonal erythrocytosis resulting from constitutive activation of the Janus Kinase and Signal Transducer and Activator of Transcription (*JAK-STAT)* signal transduction pathway. The diagnosis of PV is based on the 2016 World Health Organization (WHO) criteria utilizing a composite assessment of clinical and laboratory features^[@CR1]^. PV is associated with burdensome symptoms, reduced quality of life and thrombohemorrhagic complications with potential for myelofibrotic and/or leukemic transformation^[@CR2]^. Thrombotic complications are a major cause of morbidity and mortality with a reported incidence of 12--39%^[@CR3]^. Patients suffer from large vessel arterial and venous thrombosis, as well as microcirculatory symptoms such as dizziness, headaches, visual disturbances, erythromelalgia, distal paresthesia and acrocyanosis^[@CR3]^. In the European Collaboration on Low-Dose Aspirin in Polycythemia Vera (ECLAP) prospective study, age older than 65 years and prior thrombotic events were identified as risk factors for cardiovascular events among PV patients^[@CR4]^. Importantly, arterial and venous thrombosis are two biologically different processes with distinct risk factors. The International Working Group on Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) identified prior arterial events and hypertension as risk factors for arterial thrombosis and prior venous events and age ≥ 65 years as risk factors for venous thrombosis in PV^[@CR5]^. In this single center study, we sought to validate the findings of the IWG-MRT based on WHO 2016 PV diagnostic criteria, as well as identify additional risk factors for arterial versus venous thrombosis, including possible associations with the most frequent "non-driver" mutations: Tet methylcytosine dioxygenase 2 (*TET2)* (22%) and Additional sex combs like-1 (*ASXL1)* (12%)^[@CR6]^.

Material and methods {#Sec2}
====================

The current study was approved by the institutional review board of Mayo Clinic (Rochester, MN). Study patients were selected from our institutional database of MPN and fulfilled the 2016 WHO criteria for the diagnosis of PV^[@CR1]^. Clinical and laboratory data was obtained from the time of diagnosis. Only major thrombotic events were considered specifically: 1) Arterial thrombosis: acute myocardial infarction (MI), angina pectoris, ischemic stroke, transient ischemic attack (TIA), peripheral arterial disease (PAD) or 2) Venous thrombosis: pulmonary embolism (PE), deep vein thrombosis (DVT), portal or mesenteric thrombosis (splanchnic vein thrombosis), cerebral sinus vein thrombosis. Thrombotic events were objectively identified based on diagnostic imaging. Post-PV thrombotic events were defined as events occurring ≥ 4 weeks following PV diagnosis. Major hemorrhage was defined based on International Society on Thrombosis and Hemostasis (ISTH) definitions as: gastrointestinal, internal organ, intraarticular, cerebrovascular, retroperitoneal bleed or any bleeding requiring medical and/or surgical intervention, hospitalization and/or resulting in death. Therapy in the study included low dose Aspirin (81 mg PO once daily) and cytoreductive therapy including: hydroxyurea, busulfan, interferon, anagrelide, and JAK inhibitors. Cytogenetic analysis and reporting was done according to the International System for Human Cytogenetic Nomenclature^[@CR7]^. In addition to *JAK2V617F* and *exon 12* testing, mutation screening for *TET2* and *ASXL1* was performed according to conventional methods^[@CR6],[@CR8]^. Differences in the distribution of continuous variables between categories were analyzed by either Mann--Whitney (for comparison of two groups) or Kruskal--Wallis test (comparison of three or more groups). Patient groups with nominal variables were compared by *χ* ^2^-test. Thrombosis-free survival (TFS) was determined from the time of diagnosis to the time of event occurrence after diagnosis (uncensored) or last contact/date of death (censored). All survival curves were prepared by the Kaplan--Meier methods and compared by the log-rank test. Cox proportional hazard regression model was applied to carry out multivariate analysis. We considered *p*-values less than 0.05 as significant. The Stat View (SAS Institute, Cary, NC, USA) statistical package was used for all calculations.

Results {#Sec3}
=======

Among a total of 587 patients, the median age of our cohort was 60 years (range; 17--94 years) with 48% males. Based on current European Leukemia Net (ELN) classification^[@CR9]^, 64% were "high risk" PV (age ≥ 60 years and/or history of prior thrombosis). Patient characteristics are outlined in Table [1](#Tab1){ref-type="table"}. The incidence of cardiovascular risk factors was as follows: hypertension (42%), diabetes (9%), hyperlipidemia (21%), and history of active or remote smoking (29%). As expected, the majority of patients were *JAK2* mutated (99%) with 18 and 11% harboring *TET2* and *ASXL1* mutations, respectively. At a median follow up of 109 months, 14 and 4% of patients experienced myelofibrotic and leukemic transformation, respectively.Table 1Clinical and laboratory characteristics of 587 patients with PVVariablesAll patients (*n* = 587)Age at diagnosis (years); median (range)60 (17--94)Age ≥ 60289 (49%)Females303 (52%)Leukocytes ≥ 11 × 10^9^/L (*N* = 505)284 (56%)Platelets, × 10^9^/L; median (range)476 (41--2747)Hypertension (*N* = 581)242 (42%)Diabetes (*N* = 584)52 (9%)Hyperlipidemia (*N* = 581)123 (21%)Active smokers (*N* = 575)64 (11%)Cytogenetics (*N* = 239)Normal karyotype193 (81%)Palpable splenomegaly (*N* = 506)155 (31%)Major hemorrhage (*N* = 519)20 (4%)Conventional PV risk stratification:Low risk211 (36%)High risk376 (64%)Treatments:Phlebotomy472 (80%)Low dose ASA437 (74%)Cytoreductive therapy480 (82%)*TET2* (*N* = 133)24 (18%)*ASXL1* (*N* = 133)14 (11%)Median follow-up109 monthsLeukemic transformation23 (4%)Myelofibrotic transformation81 (14%)Deaths224 (28%)*L* liter, *PV* polycythemia vera

A total of 235 (40%) patients experienced any thrombotic event which included 153 (26%) arterial and 104 (18%) venous thromboses. One hundred forty-six patients (25%) had a thrombotic event prior to or at the time of diagnosis followed by 40 (27%) of patients with a recurrent event after PV diagnosis. Overall, post diagnosis, a total of 128 (22%) thrombotic events occurred with 11 (5%) of PV patients having experienced both an arterial and venous event. Table [2](#Tab2){ref-type="table"} outlines the type of arterial and venous events with acute coronary syndrome (ACS) being the most common arterial events (45%) experienced before or at time of diagnosis and cerebrovascular events occurring most commonly post-diagnosis (44%). In comparison, splanchnic vein thrombosis (45%) represented the most common venous events before or at diagnosis while deep venous thrombosis (DVT) (44%) were more common venous events post-diagnosis.Table 2Details of thrombotic events experienced by patients before/at or after diagnosis of PV**Thrombotic eventThrombosisThrombosisBefore or ATAfterPV diagnosisPV diagnosis**Any thrombosis146 patients (25%)128 patients (22%)Arterial thrombosis110 (19%) events82 (14%) eventsACS (MI and angina)49 (45%)30 (37%)Cerebrovascular45 (41%)36 (44%)Peripheral arterial disease16 (15%)16 (20%)Venous thrombosis69 (12%) events57 (10%) eventsDVT25 (36%)25 (44%)PE12 (17%)10 (18%)Splanchnic vein thrombosis31 (45%)22 (39%)Cerebral sinus thrombosis1 (1%)0 (0%)*ACS* acute coronary syndrome, *DVT* deep vein thrombosis, *PE* pulmonary embolism, *PV* polycythemia vera, *MI* myocardial infarction

In multivariate analysis, prior thrombotic events (HR 1.9, CI: 1.2--2.9, *p* = 0.03) and leukocytosis (WBC ≥ 11 × 10^9^/L) (HR 1.3, CI: 0.9--2.0, *p* = 0.03) were predictive of subsequent thrombotic events in general. Specifically, prior arterial events (HR 2.7, CI: 1.7--4.5, *p* \< 0.0001) and hyperlipidemia (HR 1.8, CI: 1.1--2.9, *p* = 0.03) were predictors of subsequent arterial events. In contrast, presence of major hemorrhage at diagnosis (HR 3.4, CI: 1.2--9.7, *p* = 0.02), leukocytosis (WBC ≥ 11 × 10^9^/L) (HR 2.0, CI: 1.1--3.8, *p* = 0.002) and prior venous events (HR 2.2, CI: 0.9--4.9, *p* = 0.05) were predictive of future venous events. Non-driver mutations (*TET2* and *ASXL1*) did not significantly influence neither arterial nor venous events. Table [3](#Tab3){ref-type="table"} summarizes results from both univariate and multivariate analysis for thrombosis-free survival. Based on significant parameters obtained on multivariate analysis, thrombosis-free survival data are shown in Figs. [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}. Given the limited number of thrombotic events after diagnosis, we further explored clinical associations with arterial and venous thrombotic events occurring anytime either at or after PV diagnosis. As shown in Tables [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"}, the following salient associations were noted with arterial and venous events. Older patients (≥60years) (*p* = 0.006), patients with hypertension (*p* = 0.004), diabetes (*p* = 0.005), hyperlipidemia (*p* \< 0.0001) or with normal cytogenetics (*p* = 0.01) experienced higher rates of arterial thrombosis. In contrast, younger patients (≤60 years) (*p* = 0.0005), females (*p* = 0.008), patients with palpable splenomegaly (*p* = 0.006) and a history of major hemorrhage (*p* = 0.0002) were more likely to experience venous thrombotic events. Patients who experienced a venous event were less likely to have cardiovascular risk factors: hypertension, hyperlipidemia or be active smokers.Table 3Univariate and Multivariate analysis of thrombosis-free survival among 587 patients with PV**All thrombosisUnivariate analysisMultivariate analysis**Prior thrombotic eventsHR 1.8, CI:1.2--2.6, *p* = 0.002HR 1.9, CI: 1.2--2.9, *p* = 0.03Leukocytosis (WBC ≥ 11 × 10^9^/L)HR 1.4, CI: 0.9--2.1, *p* = 0.03HR 1.3, CI: 0.9--2.0, *p* = 0.03Arterial thrombosisPrior arterial eventsHR 3.1, CI: 1.9--4.9, *p* \< 0.0001HR 2.7, CI:1.7--4.5, *p* \< 0.0001HyperlipidemiaHR 2.2, CI:1.4--3.6, *p* = 0.001HR 1.8, CI:1.1--2.9, *p* = 0.03HypertensionHR 1.7, CI: 1.1--2.6, *p* = 0.02NS, *p* = 0.1Venous thrombosisPrior venous eventsHR 2.1, CI:1.0--4.7, *p* = 0.04HR 2.2, CI: 0.9--4.9, *p* = 0.05Leukocytosis (WBC ≥ 11 × 10^9^/L)HR 2.1, CI: 1.1--3.9, *p* = 0.0009HR 2.0, CI:1.1--3.8, *p* = 0.002Major hemorrhageHR 4.7, CI: 1.9--11.0, *p* = 0.0004HR 3.4, CI:1.2--9.7, *p* = 0.02*WBC* white blood count, *L* liter, *PV* polycythemia vera Fig. 1Arterial thrombosis-free survival based on multivariate analysis was significantly affected by **a** prior arterial events and **b** hyperlipidemia Fig. 2Venous thrombosis-free survival based on multivariate analysis was significantly affected by **a** leukocytosis, **b** major hemorrhage and **c** prior venous thrombosis Table 4Clinical and laboratory features associated with arterial thrombosis among 587 patients with PV**VariablesPatients without arterial thrombotic eventsPatients with arterial thrombotic events*P*** **value(** ***n*** ** = 434)(** ***n*** ** = 153)**Age at diagnosis (years), median (range)59 (17--91)63 (28--94)0.001Age ≥ 60, *n* (%)199 (46%)90 (59%)0.006Female, *n* (%)227 (52%)76 (50%)0.6Leukocytes, × 10^9^/L, median (range)11.5 (3.8--59.3)12.1 (4.3--171.6)0.2Leukocytes ≥ 11 × 10^9^/L, median (range) (*N* = 505)207 (55%)77 (58%)0.6Platelets, × 10^9^/L, median (range)467 (44--2747)494 (44--2747)0.9Palpable splenomegaly (*N* = 506)125 (34%)30 (26%)0.02Hypertension (*N* = 581)164 (38%)78 (52%)0.004Diabetes (*N* = 584)30 (7%)22 (14%)0.005Hyperlipidemia (*N* = 581)70 (16%)53 (35%)\<0.0001Active smokers (*N* = 575)51 (12%)13 (9%)0.3Major hemorrhage (*N* = 519)15 (4%)5 (4%)0.8Cytogenetics (*N* = 239)Normal karyotype162 (78%)31 (97%)0.01*JAK2* (*N* = 560)406 (99%)146 (97%)0.1*TET2* (*N* = 133)18 (20%)6 (14%)0.4*ASXL1* (*N* = 133)9 (10%)5 (12%)0.8*L* liter, *PV* polycythemia vera Table 5Clinical and laboratory features associated with venous thrombosis among 587 patients with PV**VariablesPatients without venous thrombotic eventsPatients with venous thrombotic events*P*** **value(** ***n*** ** = 483)(** ***n*** ** = 104)**Age at diagnosis (years), median (range)61 (17--94)54 (17--89)\<0.0001Age ≥ 60 years, *n* (%)254 (53%)35 (34%)0.0005Female, *n* (%)237 (49%)66 (63%)0.008Leukocytes, × 10^9^/L, median (range)11.5 (3.8--59.3)12.3 (4.7--171.6)0.5Leukocytes ≥ 11 × 10^9^/L, median (range) (*N* = 505)230 (55%)54 (61%)0.4Platelets, × 10^9^/L, median (range)493 (41--2747)408 (97--1550)0.001Palpable splenomegaly (*N* = 506)118 (28%)37 (43%)0.006Erythromelagia (*N* = 504)28 (7%)10 (11%)0.2Hypertension (*N* = 581)211 (44%)31 (30%)0.009Diabetes (*N* = 584)43 (9%)9 (9%)0.9Hyperlipidemia (*N* = 581)112 (23%)11 (11%)0.004Active smokers (*N* = 575)59 (12%)5 (5%)0.03Major hemorrhage, (*N* = 519)10 (2%)10 (11%)0.0002Cytogenetic (*N* = 239)Normal karyotype178 (80%)15 (88%)0.4*JAK2* (*N* = 560)452 (98%)100 (99%)0.7*TET2 (N* = 133)20 (19%)4 (15%)0.7*ASXL1 (N* = 133)11 (10%)3 (12%)0.9*L* liter, *PV* polycythemia vera

Discussion {#Sec4}
==========

In the current large series of PV patients that were evaluated and carefully followed at a single institution, we were able to systematically analyze the differences in risk factors for arterial versus venous thrombosis. In our study, the incidence of arterial (17%) and venous thrombosis (9%) before or at PV diagnosis, were similar to prior studies; ECLAP (27 and 11%, respectively), CYTO-PV (17 and 12%, respectively) and IWG-MRT study (16 and 7.4%, respectively)^[@CR4],[@CR5],[@CR10],^. Twenty-two percent of our patients experienced a thrombotic event after diagnosis (2.4%/year), which was also similar to the CYTO-PV and ECLAP studies (2.7/year and 2.6%/year, respectively), but lower than the IWG-MRT study (4.4%/year)^[@CR4],[@CR5],[@CR10]^.

We confirm that a history of arterial and/or venous thrombosis is the most reliable risk factor for future arterial and venous events as shown in the IWG-MRT study^[@CR5]^. A novel observation is the association of leukocytosis with increased risk of all thrombotic events, specifically venous thrombosis which differs from the findings of the ECLAP study in which leukocytosis ≥ 15 × 10^9^/L was associated with increased cardiovascular events among PV patients^[@CR4]^. Leukocytosis is also a well-established risk factor for thrombosis and inferior survival among essential thrombocytosis (ET) patients^[@CR11]--[@CR13]^.

The role of cardiovascular risk factors in thrombosis was explored, with hyperlipidemia having an impact on future arterial thrombosis. As expected, we identified older age (≥ 60 years), hypertension, diabetes, hyperlipidemia, and normal karyotype to be associated with increased risk of overall arterial thrombosis. In contrast, younger patients, females, patients with palpable splenomegaly and a history of major hemorrhage were more likely to experience a venous thrombotic event. The IWG-MRT had also identified this association of female gender and venous thrombosis which may be related to use of concomitant hormonal therapy but was not specifically evaluated in either study^[@CR5]^. The association of splenomegaly and thrombosis has been evaluated in ET with conflicting results^[@CR14],[@CR15]^.

In conclusion, our study reinforces the importance of a history of thrombosis in predicting future thrombotic events and supports that arterial and venous events are distinct entities with specific risk factors that require careful evaluation and management. Additionally, the non-driver *TET2* and *ASXL1* mutations did not impact arterial nor venous thrombosis. Further studies are needed to conclusively confirm the role of specific risk factors identified for arterial versus venous thrombosis.
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